@ARTICLE{
author={Magro F,Tilg H,Cataldi F,Jacobstein D,Rabbat C,Shan K,Nancey S,Markovic S,Rocco R,Harlacher L,Yarur A},
year={2026},
title={Impact of age of subjects on the efficacy and safety of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials},
journal={JOURNAL OF CROHNS & COLITIS},
volume={20},
number={},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Armuzzi A,Atreya R,Sparrow MP,Markovic S,Le Berre C,Hlavaty T,Treton X,Cataldi F,Jacobstein D,Rabbat C,Shan K,Dubinsky MC},
year={2026},
title={Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials},
journal={JOURNAL OF CROHNS & COLITIS},
volume={20},
number={},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={D'Haens Geert R,Reinisch Walter,Lee SD,Tarabar Dino K,Louis E,Klopocka M,Klaus J,Schreiber S,Park DI,Hebuterne Xavier,Cataldi F,Banerjee A,Gorelick K,Sandborn William J},
year={2018},
title={Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn's disease: the OPERA II study},
journal={JOURNAL OF CROHNS & COLITIS},
volume={12},
number={},
pages={S17-S18},
document_type={Meeting Abstract},
}